Abstract
The cancer stem cell (CSC) hypothesis presents a fundamentally different paradigm for cancer treatment. CSCs reflect a small fraction of tumor initiating cells capable of sustained self-renewal and differentiation to form the heterogeneous tumor bulk. In order to cure cancer, it is necessary to eliminate cancer stem cells in addition to differentiated cancer cells to decrease metastasis, reduce recurrence, and improve patient survival. In this article, we review cancer stem cell signaling pathways, including Wnt, Hedgehog, and Notch, as well as interactions of CSCs with the tumor microenvironment. We also review methods to isolate CSCs and demonstrate therapeutic efficacy of natural products to modulate these signaling pathways for eliminating CSCs.
Keywords: Akt, cancer stem cell, hedgehog, HIF-1α, natural product, NF-κB, notch, Wnt signaling, tumor, metastasis
Current Drug Targets
Title:Targeting Cancer Stem Cells with Natural Products
Volume: 13 Issue: 8
Author(s): Joseph Burnett, Bryan Newman and Duxin Sun
Affiliation:
Keywords: Akt, cancer stem cell, hedgehog, HIF-1α, natural product, NF-κB, notch, Wnt signaling, tumor, metastasis
Abstract: The cancer stem cell (CSC) hypothesis presents a fundamentally different paradigm for cancer treatment. CSCs reflect a small fraction of tumor initiating cells capable of sustained self-renewal and differentiation to form the heterogeneous tumor bulk. In order to cure cancer, it is necessary to eliminate cancer stem cells in addition to differentiated cancer cells to decrease metastasis, reduce recurrence, and improve patient survival. In this article, we review cancer stem cell signaling pathways, including Wnt, Hedgehog, and Notch, as well as interactions of CSCs with the tumor microenvironment. We also review methods to isolate CSCs and demonstrate therapeutic efficacy of natural products to modulate these signaling pathways for eliminating CSCs.
Export Options
About this article
Cite this article as:
Burnett Joseph, Newman Bryan and Sun Duxin, Targeting Cancer Stem Cells with Natural Products, Current Drug Targets 2012; 13 (8) . https://dx.doi.org/10.2174/138945012802009062
DOI https://dx.doi.org/10.2174/138945012802009062 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Current Pharmaceutical Design Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) 3D Cell and Scaffold Patterning Strategies in Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Recent Patents on Electrospun Biomedical Nanostructures: An Overview
Recent Patents on Biomedical Engineering (Discontinued) The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Posterior Internal Frontal Artery Vascularization of the Precentral Gyrus Responsible for Proximal Arm Movement: Insight from a Case of Coil Migration
Current Neurovascular Research Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Contribution of Platelet-Derived CD40 Ligand to Inflammation, Thrombosis and Neoangiogenesis
Current Medicinal Chemistry Targets for Medical Therapy to Limit Abdominal Aortic Aneurysm Progression
Current Drug Targets Secondary Prevention of Ischemic Stroke
Current Drug Targets Spectrophotometric Quantification of Bilirubin in Hemorrhagic Spinal Fluid using an Innovative Algorithm
Medicinal Chemistry Safety of Intravenous Thrombolysis in Ischemic Stroke Caused by Left Atrial Myxoma
Current Drug Safety Review: Therapeutic Targeting of HMGB1 in Stroke
Current Drug Delivery Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Neurological Disorders in Pregnancy
Current Women`s Health Reviews